Net revenue and net profit after tax both increased year-over-year, with strong gross margins and higher equity. Significant cash outflows for investments and dividends reduced liquidity, but the company maintained stable operations in the pharmaceutical sector.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.